CareDx has secured IVDR certification from the European Union for its AlloSeq Tx and QType next-generation sequencing and RT-PCR-based HLA typing products. These platforms enhance compatibility analysis in organ and stem cell transplantation, contributing to precision in donor-recipient matching. The company unveiled AlloSeq Tx11, improving Class II coverage and integrating non-HLA markers like ABO and APOL1 to broaden transplant risk profiling. Software updates and a new HLA typing assay featuring long-read genotyping and rapid turnaround were also announced, underlining CareDx's commitment to innovation in transplant diagnostics.